CL2017000498A1 - Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013) - Google Patents

Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)

Info

Publication number
CL2017000498A1
CL2017000498A1 CL2017000498A CL2017000498A CL2017000498A1 CL 2017000498 A1 CL2017000498 A1 CL 2017000498A1 CL 2017000498 A CL2017000498 A CL 2017000498A CL 2017000498 A CL2017000498 A CL 2017000498A CL 2017000498 A1 CL2017000498 A1 CL 2017000498A1
Authority
CL
Chile
Prior art keywords
galns
formulation
sulfatase
acetylgalactosamine
divisional application
Prior art date
Application number
CL2017000498A
Other languages
English (en)
Inventor
Vish Koppaka
Michel Claude Vellard
Kidisti Araya
Augustus O Okhamafe
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CL2017000498A1 publication Critical patent/CL2017000498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>UNA FORMULACIÓN QUE INCLUYE DICHA ENZIMA (GALNS) ÚTIL PARA EL DIAGNÓSTICO, PROFILAXIS O TRATAMIENTO DE ENFERMEDADES Y CONDICIONES, CAUSADAS POR ALMACENAMIENTO LISOSOMAL O ASOCIADAS CON UNA DEFICIENCIA EN LA ENZIMA GALNS, POR EJEMPLO, LA MUCOPOLISACARIDOSIS IVa (MPS IVa O SÍNDROME DE MORQUIO A).</p>
CL2017000498A 2010-07-22 2017-03-02 Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013) CL2017000498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36671410P 2010-07-22 2010-07-22

Publications (1)

Publication Number Publication Date
CL2017000498A1 true CL2017000498A1 (es) 2017-11-24

Family

ID=44543776

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013000219A CL2013000219A1 (es) 2010-07-22 2013-01-22 Método para la purificación de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada (galns); composición purificada que comprende galns; método para la prevención de la desfosforilación de una enzima galns.
CL2017000498A CL2017000498A1 (es) 2010-07-22 2017-03-02 Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013000219A CL2013000219A1 (es) 2010-07-22 2013-01-22 Método para la purificación de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada (galns); composición purificada que comprende galns; método para la prevención de la desfosforilación de una enzima galns.

Country Status (28)

Country Link
US (3) US8765437B2 (es)
EP (1) EP2595650B1 (es)
JP (2) JP6030553B2 (es)
KR (2) KR101949906B1 (es)
CN (1) CN103037895B (es)
AR (2) AR082319A1 (es)
AU (1) AU2011280937B2 (es)
BR (1) BR112013001558B1 (es)
CA (2) CA2805673C (es)
CL (2) CL2013000219A1 (es)
CY (1) CY1118934T1 (es)
DK (1) DK2595650T3 (es)
ES (1) ES2616263T3 (es)
HR (1) HRP20170245T1 (es)
HU (1) HUE033163T2 (es)
IL (2) IL224125B (es)
LT (1) LT2595650T (es)
MX (1) MX341838B (es)
PE (3) PE20171799A1 (es)
PL (1) PL2595650T3 (es)
PT (1) PT2595650T (es)
RS (1) RS55669B1 (es)
RU (1) RU2607376C2 (es)
SG (1) SG187580A1 (es)
SI (1) SI2595650T1 (es)
SM (1) SMT201700106B (es)
WO (1) WO2012012718A2 (es)
ZA (1) ZA201300286B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3219795T (lt) * 2008-01-18 2024-07-25 Biomarin Pharmaceutical Inc. Aktyvių, aukšto fosforilinimo lygio žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2013119715A1 (en) * 2012-02-07 2013-08-15 Saint Louis University Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US11529397B2 (en) 2018-01-22 2022-12-20 Saint Louis University Method of treating mucopolysaccharidosis type IVA
US9453046B2 (en) 2013-03-13 2016-09-27 Seattle Genetics, Inc. Activated carbon filtration for purification of benzodiazepine ADCs
CA2902629A1 (en) 2013-03-13 2014-10-02 Shire Human Genetic Therapies, Inc. Method of characterizing lysosomal enzymes
US9827295B2 (en) * 2013-05-15 2017-11-28 Regents Of The University Of Minnesota Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase
WO2014201220A1 (en) * 2013-06-12 2014-12-18 The Board Of Trustees Of The University Of Illinois Methods for detecting prostate cancer
WO2015005961A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation A method of determining virus removal from a sample containing a target protein using activated carbon
EP3912635A1 (en) * 2014-07-11 2021-11-24 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10472615B2 (en) 2016-01-21 2019-11-12 Saint Louis University Reduced immunogenic proteins for lysosomal storage disorders
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
JP6957738B2 (ja) * 2017-08-31 2021-11-02 グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． スルファターゼタンパク質を精製する方法
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
US20230193205A1 (en) * 2020-04-19 2023-06-22 Figene, Llc Gene modified fibroblasts for therapeutic applications
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPS62122588A (ja) 1985-11-22 1987-06-03 Taiyo Fishery Co Ltd 純コンドロイチナ−ゼの製造法
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
RU2195492C2 (ru) * 2000-09-04 2002-12-27 Институт физиологии Коми научного центра Уральского отделения РАН Способ получения пектолитического ферментного препарата
JP4307079B2 (ja) 2001-01-26 2009-08-05 セレキス エスアー マトリックス付着領域およびその使用方法
JP2006508643A (ja) * 2002-07-01 2006-03-16 アーキオン ライフ サイエンシーズ エルエルシー ディー／ビー／エー バイオ−テクニカル リソーセズ ディビジョン グルコサミンおよびｎ−アセチルグルコサミン製造のためのプロセスおよび材料
EP2325301B1 (en) 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
KR20070100299A (ko) * 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 재조합 인간 성장 호르몬의 발현 및 정제 방법
MX2008013535A (es) * 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
US20080231439A1 (en) 2007-03-22 2008-09-25 Inventec Corporation Activity Detection Circuit for a Storage Device
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
LT3219795T (lt) * 2008-01-18 2024-07-25 Biomarin Pharmaceutical Inc. Aktyvių, aukšto fosforilinimo lygio žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
US8765437B2 (en) 2014-07-01
IL224125B (en) 2019-02-28
PE20171798A1 (es) 2017-12-28
BR112013001558A2 (pt) 2020-08-04
EP2595650B1 (en) 2016-11-16
IL260282A (en) 2018-07-31
US20160186149A1 (en) 2016-06-30
IL260282B (en) 2020-05-31
AR082319A1 (es) 2012-11-28
PL2595650T3 (pl) 2017-06-30
KR101598897B1 (ko) 2016-03-03
RU2013107765A (ru) 2014-08-27
PE20131140A1 (es) 2013-10-17
US8940513B2 (en) 2015-01-27
ES2616263T3 (es) 2017-06-12
MX2013000908A (es) 2013-07-05
CN103037895B (zh) 2016-11-09
KR20130105605A (ko) 2013-09-25
SI2595650T1 (sl) 2017-04-26
CA2805673C (en) 2022-04-05
CN103037895A (zh) 2013-04-10
PE20171799A1 (es) 2017-12-28
AU2011280937A1 (en) 2013-01-31
HRP20170245T1 (hr) 2017-04-21
PT2595650T (pt) 2017-02-22
RU2607376C2 (ru) 2017-01-10
EP2595650A2 (en) 2013-05-29
CA3146151A1 (en) 2012-01-26
KR101949906B1 (ko) 2019-04-22
ZA201300286B (en) 2014-03-26
CY1118934T1 (el) 2018-01-10
US20140341878A1 (en) 2014-11-20
MX341838B (es) 2016-09-05
CL2013000219A1 (es) 2014-07-11
CA2805673A1 (en) 2012-01-26
SMT201700106B (it) 2017-03-08
BR112013001558B1 (pt) 2022-08-16
WO2012012718A3 (en) 2012-04-05
US9567572B2 (en) 2017-02-14
RS55669B1 (sr) 2017-06-30
US20120189605A1 (en) 2012-07-26
JP6030553B2 (ja) 2016-11-24
JP2016178950A (ja) 2016-10-13
SG187580A1 (en) 2013-03-28
HUE033163T2 (en) 2017-11-28
WO2012012718A2 (en) 2012-01-26
JP2013532986A (ja) 2013-08-22
KR20150038715A (ko) 2015-04-08
AU2011280937B2 (en) 2016-06-09
AR119552A2 (es) 2021-12-29
DK2595650T3 (en) 2017-02-27
LT2595650T (lt) 2017-03-10

Similar Documents

Publication Publication Date Title
CL2017000498A1 (es) Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
NL300874I2 (nl) Elosulfase alfa
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
WO2011110275A3 (en) Radiative fibers
CL2016001553A1 (es) Medios para cultivo celular
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
CL2012003656A1 (es) Uso de una composicion que comprende una enzima de reemplazo para la enzima lisosomal a una concentracion mayor a 5 mg/ml para tratar sintomas somaticos de la deficiencia de la enzima subyacente.
GT201200276A (es) Combinaciones de compuestos activos
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
MY175979A (en) Certain chemical entities, compositions and methods
MY172151A (en) Certain chemical entities, compositions and methods
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
UA117341C2 (uk) Кліщова композиція, яка включає хижого кліща та іммобілізовану жертву, що контактує зі стримуючим розвиток грибків агентом, і способи та застосування, пов&#39;язані з використанням зазначеної композиції
CL2010000829A1 (es) Metodo para tratar plantas que comprende aplicar a las plantas una composicion liquida que contiene ente 0,3 a 300 miligramos de uno o mas ciclopropenos por litro de dicha composicion.
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
UA113188C2 (xx) Спосіб одержання гідрогелю з використанням ферментів ліпаз
ES2570386T3 (es) Procedimiento de lucha biológica contra Pseusomonas
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
PH12014501307A1 (en) Liquid activation system
WO2011103458A3 (en) Compositions and methods for using and identifying antimicrobial agents
AR118157A2 (es) Una enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante, composición y sus usos